【Introduction of Vivo/Panda Fund】Michael Chang 特別演講

Date: 2016-07-22 Friday
Time: 6:00-8:30PM
Place: 台灣研發型生技新藥發展協會 TRPMA
台北市忠孝東路六段465-1號1樓
1F, No. 465-1, Sec. 6, Zhongxiao E. Rd., Nangang Dist., Taipei City 11557, Taiwan

Agenda
1. 18:00 - 19:15 Register and refreshments
2. 19:15 - 19:45 Introduction of Vivo/Panda Fund
3. 19:45 - 20:30 Introduction of MEDX teams

【Speaker】
Michael Chang joined Vivo with a background in healthcare strategy and operations in both the U.S. and China. Prior to Vivo, he worked at Johnson & Johnson, where he helped establish the strategy and commercial planning function for J&J’s China medical device business. Previously, he worked for Booz & Company and Fletcher Spaght, and also co-founded a company in the vascular access space.
Michael graduated from Harvard University with a B.A. in Economics, with a focus on health policy, and an M.B.A. from Harvard Business School. He also has research experience at Harvard Medical School and University of California Irvine in brain tumor immunology and cancer genetics.

【Vivo Capital / PANDA Fund】
Founded in 1996, Vivo Capital is a healthcare investment firm focused on investing in and building high quality companies in the U.S. and China. With more than $1.7 billion under management, Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising development stage and commercial stage therapeutic products in the U.S. and revenue stage companies in China. Vivo Capital has offices in Palo Alto, California, Shanghai, and Beijing, China.

PANDA stands for Vivo"s "Pre- AND-series A" and is a new Taiwan-Silicon Fund.

【MEDX】
- Inspired and sponsored by Dr. Hongjen Chang
- Informal dinners in Taipei with medtech entrepreneurs and invited thought leaders
- Build connections and relationships in the Taiwan medtech community
- Dialog about opportunities and challenges in medtech innovation

【聚會贊助者】
台灣研發型生技新藥發展協會 TRPMA
Taiwan Research-based Biopharmaceutical Manufacturers Association
http://www.trpma.org.tw/index.php/en/about-trpma-en/introduction-en

此刻正是我國研發型生技產業成功的關鍵時刻，因此我們結合了從事新藥研發的生技公司成立了台灣研發型生技新藥發展協會，期望以創新的精神，積極合作的態度，加強與政府學界溝通協調，加速資源整合，法規建立以及市場佈局，以迎接台灣生技新藥的成功上市。未來，台灣研發型生技新藥發展協會的任務將包括：
1.成為台灣與全球生技新藥研發合作的窗口
2.積極參與兩岸生技醫療產業合作
3.推動台灣生技醫療產業發展政策
4.支持全民健保與藥政管理各項政策
5.建立研發型生技新藥產業專業平台